Mon premier blog

Polymorphism in the pharmaceutical industry Rolf Hilfiker
Publisher: Wiley-VCH

Ten or 20 years from now, we will be sending our patients to the laboratory to characterize them in terms of genetic polymorphisms and/or to an imaging laboratory. Pharmacogenomics in clinical trials is a relatively new area in which considerable hesitation is shown by pharmaceutical companies. Now, we are focusing on polymorphism and pseudo polymorphism, which is not only an academic challenge, but has great relevance for the pharmaceutical industry. Polymorphism – is your pharmaceutical company in good shape? What are some of the applications of crystal engineering? Similarly, polymorphisms of transporters . Polymorphism: in the Pharmaceutical Industry http://www.paid4share.com/file/4324/3527311467-rar.html. Its activities are based on the hypothesis that there is some The structure of the Consortium, now moving into its second phase, was informed by the SNP [single nucleotide polymorphism] Consortium, which Holden also organised and led. _ Naturally, polymorphisms in drug-metabolizing enzymes is an important factor that is well known, described, and included in the Medical Compendium designed for physicians; yet, these polymorphisms are not widely taken into consideration targets, including rhodopsin-like G protein– coupled receptors (GPCR), protein kinases, ion channels, proteases, and enzymes, as they have classically been used by the pharmaceutical industry before the use of novel genomic technologies. Polymorphism of drugs has been the subject of intense interest in the pharmaceutical industry for over forty years. In his painstakingly 275-page decision, the single judge, Justice Manmohan Singh opined that the generic product Erlocip manufactured and sold by Cipla contains polymorphic B variant of Erlotinib hydrochloride as active ingredient and hence do not infringed the compound per se claims of the It is likely that the reasoning of this decision may add yet another disappointment and further dismay for the pharmaceutical companies in enforcing their patents in India . Polymorphism In Pharmaceutical Industry http://rapidshare.com/files/94365103/New_Folder__2_.rar. The Consortium brings together the Wellcome Trust, medicines regulators, academic researchers and representatives from ten multinational pharmaceutical companies. Variations in drug response due to polymorphism of receptors can be illustrated with β2 adrenergic receptor polymorphisms, where homozygous mutants with decreased expression of β2 adrenergic receptors do not have a predictable response to the use of drugs like salbutamol in asthma. Then based on those findings, and on the In the meantime, these companies are selling their services to pharmaceutical companies for research into new drugs to fill this soon-to-be-discovered future need – gearing up to create a new pipeline for the drug trade.